Chemotherapy and Drug Information

QOL, Adverse Effects Better With Capecitabine After Adjuvant Epirubicin for Breast Cancer

QOL, Adverse Effects Better With Capecitabine After Adjuvant Epirubicin for Breast Cancer

Women with breast cancer who received capecitabine after adjuvant epirubicin had better quality of life (QOL) compared with those who received CMF after adjuvant therapy.

Taxane-based Chemotherapy May Diminish Balance, Gait in Breast Cancer Survivors

Taxane-based Chemotherapy May Diminish Balance, Gait in Breast Cancer Survivors

Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

Doxorubicin Efficacy Improved, Cardiotoxicity Reduced With Adjuvant Fidarest for Colon Cancer

The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

Wait Times From Cancer Diagnosis to First Treatment Longer, Negative Impact on Survival

Data from the National Cancer Database are indicating that wait times from cancer diagnosis to initial treatment were substantially longer over a 5-year period.

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Improved Outcomes in Lung Cancer With Hyperfractionated Chemoradiation Therapy

Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC

Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.

Ovarian Function Recovery May Increase Risk of Breast Cancer Recurrence

Ovarian Function Recovery May Increase Risk of Breast Cancer Recurrence

Ovarian function recovery (OFR) in women with chemotherapy-induced ovarian function failure decreases residual 5-year disease-free and overall survival.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Efficacy of Trastuzumab Biosimilars Shown Equivalent to Originator in HER2 Breast Cancer

Efficacy of Trastuzumab Biosimilars Shown Equivalent to Originator in HER2 Breast Cancer

Biosimilars and originator trastuzumab neoadjuvant therapy had a comparable effect on pathologic complete response rates.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs